[8-K] Kindly MD, Inc. Reports Material Event

Rhea-AI Filing Summary

KindlyMD (NASDAQ:NAKA) filed an 8-K announcing the appointment of Andrew Creighton as Chief Commercial Officer of Nakamoto Holdings. The filing indicates this is a Regulation FD disclosure, with the information being furnished rather than filed under Section 18 of the Securities Exchange Act. The company, which is classified as an emerging growth company, made this announcement via press release on June 25, 2025.

Insights

Corporate Governance Expert

Executive appointment signals potential commercial expansion but relationship between entities requires clarity.

The appointment of Andrew Creighton as Chief Commercial Officer of Nakamoto Holdings, while disclosed by KindlyMD, raises interesting governance considerations. The filing's structure suggests an important relationship between KindlyMD and Nakamoto Holdings that isn't fully explained in this disclosure. The choice to file this under Regulation FD indicates the information is deemed material enough for broad public dissemination, though technically not filed under Section 18 of the Exchange Act.

false 0001946573 0001946573 2025-06-25 2025-06-25 0001946573 NAKA:CommonStockParValue0.001Member 2025-06-25 2025-06-25 0001946573 NAKA:TradeableWarrantsToPurchaseSharesOfCommonStockParValue0.001PerShareMember 2025-06-25 2025-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 25, 2025

Kindly MD, Inc.

(Exact name of registrant as specified in its charter)

001-42103		84-3829824
(Commission File Number)		(IRS Employer Identification Number)
5097 South 900 East, Suite 100, Salt Lake City, UT		84117
(Address of Principal Executive Offices)		(Zip Code)

(385) 388-8220
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001		NAKA		The Nasdaq Stock Market LLC
Tradeable Warrants to purchase shares of Common Stock, par value $0.001 per share		NAKAW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 25, 2025, Nakamoto Holdings, Inc. (“Nakamoto”) and KindlyMD Inc. (the “Company”) issued a press release announcing the appointment of Andrew Creighton as Nakamoto’s Chief Commercial Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, will not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Press Release, dated as of June 25, 2025
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunder duly authorized.

	KINDLY MD, INC.
Dated: June 25, 2025	By:	/s/ Tim Pickett
		Tim Pickett
		Chief Executive Officer

FAQ

Who is Andrew Creighton and what is his new role at Nakamoto Holdings?

Andrew Creighton has been appointed as the Chief Commercial Officer of Nakamoto Holdings. The filing does not provide additional details about his background or previous experience.

What is the relationship between KindlyMD and Nakamoto Holdings?

While the filing shows that KindlyMD is reporting Nakamoto Holdings' executive appointment, the exact relationship between the two entities is not explicitly detailed in this 8-K filing.

Is KindlyMD (NAKA) an emerging growth company?

Yes, the filing explicitly indicates that KindlyMD is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934.